Financhill
Sell
35

DXCM Quote, Financials, Valuation and Earnings

Last price:
$70.67
Seasonality move :
9.96%
Day range:
$68.30 - $70.72
52-week range:
$62.34 - $142.00
Dividend yield:
0%
P/E ratio:
47.89x
P/S ratio:
7.01x
P/B ratio:
12.73x
Volume:
3.4M
Avg. volume:
4M
1-year change:
-48%
Market cap:
$26.8B
Revenue:
$4B
EPS (TTM):
$1.43

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DXCM
DexCom
$1.1B $0.50 10.44% -9.12% $101.79
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.26
AXGN
Axogen
$49.4M $0.04 17.91% -76% $25.00
EW
Edwards Lifesciences
$1.4B $0.55 -12.34% 2.73% $80.42
PODD
Insulet
$582M $1.02 23.07% 6.17% $314.06
TNDM
Tandem Diabetes Care
$251.4M -$0.24 14.85% -7.32% $41.65
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DXCM
DexCom
$68.48 $101.79 $26.8B 47.89x $0.00 0% 7.01x
ABT
Abbott Laboratories
$129.89 $136.26 $225.3B 16.98x $0.59 1.73% 5.41x
AXGN
Axogen
$17.16 $25.00 $760.9M -- $0.00 0% 4.05x
EW
Edwards Lifesciences
$67.95 $80.42 $39.9B 9.75x $0.00 0% 7.11x
PODD
Insulet
$244.67 $314.06 $17.2B 42.26x $0.00 0% 8.73x
TNDM
Tandem Diabetes Care
$18.18 $41.65 $1.2B -- $0.00 0% 1.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DXCM
DexCom
53.73% 1.028 8.03% 1.23x
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
AXGN
Axogen
31.37% 0.673 6.53% 1.88x
EW
Edwards Lifesciences
5.64% 1.315 1.37% 3.12x
PODD
Insulet
53.47% 1.510 7.6% 2.50x
TNDM
Tandem Diabetes Care
57.01% 2.440 14.62% 2.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DXCM
DexCom
$655.8M $188.9M 12.52% 26.6% 19.42% $176.8M
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
EW
Edwards Lifesciences
$1.1B $353.3M 47.36% 50.81% 31.83% -$181.9M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M
TNDM
Tandem Diabetes Care
$157.5M -$582K -16.17% -37.18% -0.01% -$38.8M

DexCom vs. Competitors

  • Which has Higher Returns DXCM or ABT?

    Abbott Laboratories has a net margin of 13.62% compared to DexCom's net margin of 84.1%. DexCom's return on equity of 26.6% beat Abbott Laboratories's return on equity of 32.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    DXCM
    DexCom
    58.9% $0.38 $4.5B
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
  • What do Analysts Say About DXCM or ABT?

    DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Abbott Laboratories has an analysts' consensus of $136.26 which suggests that it could grow by 4.91%. Given that DexCom has higher upside potential than Abbott Laboratories, analysts believe DexCom is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    DXCM
    DexCom
    17 3 0
    ABT
    Abbott Laboratories
    13 6 0
  • Is DXCM or ABT More Risky?

    DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.

  • Which is a Better Dividend Stock DXCM or ABT?

    DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.73% to investors and pays a quarterly dividend of $0.59 per share. DexCom pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DXCM or ABT?

    DexCom quarterly revenues are $1.1B, which are smaller than Abbott Laboratories quarterly revenues of $11B. DexCom's net income of $151.7M is lower than Abbott Laboratories's net income of $9.2B. Notably, DexCom's price-to-earnings ratio is 47.89x while Abbott Laboratories's PE ratio is 16.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 5.41x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DXCM
    DexCom
    7.01x 47.89x $1.1B $151.7M
    ABT
    Abbott Laboratories
    5.41x 16.98x $11B $9.2B
  • Which has Higher Returns DXCM or AXGN?

    Axogen has a net margin of 13.62% compared to DexCom's net margin of 0.91%. DexCom's return on equity of 26.6% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    DXCM
    DexCom
    58.9% $0.38 $4.5B
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About DXCM or AXGN?

    DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 45.69%. Given that DexCom has higher upside potential than Axogen, analysts believe DexCom is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    DXCM
    DexCom
    17 3 0
    AXGN
    Axogen
    4 0 0
  • Is DXCM or AXGN More Risky?

    DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

  • Which is a Better Dividend Stock DXCM or AXGN?

    DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DXCM or AXGN?

    DexCom quarterly revenues are $1.1B, which are larger than Axogen quarterly revenues of $49.4M. DexCom's net income of $151.7M is higher than Axogen's net income of $450K. Notably, DexCom's price-to-earnings ratio is 47.89x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 4.05x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DXCM
    DexCom
    7.01x 47.89x $1.1B $151.7M
    AXGN
    Axogen
    4.05x -- $49.4M $450K
  • Which has Higher Returns DXCM or EW?

    Edwards Lifesciences has a net margin of 13.62% compared to DexCom's net margin of 27.83%. DexCom's return on equity of 26.6% beat Edwards Lifesciences's return on equity of 50.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    DXCM
    DexCom
    58.9% $0.38 $4.5B
    EW
    Edwards Lifesciences
    78.92% $0.65 $10.7B
  • What do Analysts Say About DXCM or EW?

    DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Edwards Lifesciences has an analysts' consensus of $80.42 which suggests that it could grow by 18.36%. Given that DexCom has higher upside potential than Edwards Lifesciences, analysts believe DexCom is more attractive than Edwards Lifesciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    DXCM
    DexCom
    17 3 0
    EW
    Edwards Lifesciences
    10 17 1
  • Is DXCM or EW More Risky?

    DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.123, suggesting its more volatile than the S&P 500 by 12.315%.

  • Which is a Better Dividend Stock DXCM or EW?

    DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DXCM or EW?

    DexCom quarterly revenues are $1.1B, which are smaller than Edwards Lifesciences quarterly revenues of $1.4B. DexCom's net income of $151.7M is lower than Edwards Lifesciences's net income of $385.6M. Notably, DexCom's price-to-earnings ratio is 47.89x while Edwards Lifesciences's PE ratio is 9.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 7.11x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DXCM
    DexCom
    7.01x 47.89x $1.1B $151.7M
    EW
    Edwards Lifesciences
    7.11x 9.75x $1.4B $385.6M
  • Which has Higher Returns DXCM or PODD?

    Insulet has a net margin of 13.62% compared to DexCom's net margin of 16.85%. DexCom's return on equity of 26.6% beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    DXCM
    DexCom
    58.9% $0.38 $4.5B
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About DXCM or PODD?

    DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 28.36%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    DXCM
    DexCom
    17 3 0
    PODD
    Insulet
    14 4 0
  • Is DXCM or PODD More Risky?

    DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

  • Which is a Better Dividend Stock DXCM or PODD?

    DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DXCM or PODD?

    DexCom quarterly revenues are $1.1B, which are larger than Insulet quarterly revenues of $597.5M. DexCom's net income of $151.7M is higher than Insulet's net income of $100.7M. Notably, DexCom's price-to-earnings ratio is 47.89x while Insulet's PE ratio is 42.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 8.73x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DXCM
    DexCom
    7.01x 47.89x $1.1B $151.7M
    PODD
    Insulet
    8.73x 42.26x $597.5M $100.7M
  • Which has Higher Returns DXCM or TNDM?

    Tandem Diabetes Care has a net margin of 13.62% compared to DexCom's net margin of 0.27%. DexCom's return on equity of 26.6% beat Tandem Diabetes Care's return on equity of -37.18%.

    Company Gross Margin Earnings Per Share Invested Capital
    DXCM
    DexCom
    58.9% $0.38 $4.5B
    TNDM
    Tandem Diabetes Care
    55.71% $0.01 $612M
  • What do Analysts Say About DXCM or TNDM?

    DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Tandem Diabetes Care has an analysts' consensus of $41.65 which suggests that it could grow by 129.1%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

    Company Buy Ratings Hold Ratings Sell Ratings
    DXCM
    DexCom
    17 3 0
    TNDM
    Tandem Diabetes Care
    8 10 0
  • Is DXCM or TNDM More Risky?

    DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.446, suggesting its more volatile than the S&P 500 by 44.616%.

  • Which is a Better Dividend Stock DXCM or TNDM?

    DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DXCM or TNDM?

    DexCom quarterly revenues are $1.1B, which are larger than Tandem Diabetes Care quarterly revenues of $282.6M. DexCom's net income of $151.7M is higher than Tandem Diabetes Care's net income of $755K. Notably, DexCom's price-to-earnings ratio is 47.89x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 1.27x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DXCM
    DexCom
    7.01x 47.89x $1.1B $151.7M
    TNDM
    Tandem Diabetes Care
    1.27x -- $282.6M $755K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Tesla Stock: The Bear Case
Tesla Stock: The Bear Case

The recent stock market drop has been a punishing time…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Alerts

Sell
5
CABO alert for Mar 14

Cable One [CABO] is down 3.97% over the past day.

Sell
38
ADBE alert for Mar 14

Adobe [ADBE] is up 4.43% over the past day.

Sell
29
CAR alert for Mar 14

Avis Budget Group [CAR] is up 11.68% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock